Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer:A Prospective Multicentre Validation Study
| Autor: | Lars Dyrskjøt, Jørgen Bjerggaard Jensen, Torben F. Ørntoft, Roman Nawroth, Arndt Hartmann, Robert Stöhr, Willemien Beukers, Niels Harving, Karin Mogensen, Cane Tulic, Benedicte Parm Ulhøi, Ulrika Segersten, Gregers G. Hermann, Mirari Marquez, Thomas Reinert, Daan Nieboer, Tobias Maurer, Sven Wach, Ewout W. Steyerberg, Astrid Christine Petersen, Ferran Algaba, Kristina Schwamborn, Søren Høyer, Francisco X. Real, Kerstin Junker, Per-Uno Malmström, Núria Malats, Ellen C. Zwarthoff, Tatjana Simic, Marc-Oliver Grimm, Emil Christensen, Marcus Horstmann, Bastian Keck |
|---|---|
| Přispěvatelé: | Public Health, Pathology |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Validation study Urology Disease 03 medical and health sciences 0302 clinical medicine SDG 3 - Good Health and Well-being Internal medicine medicine Journal Article 10. No inequality Patient summary Prospective cohort study Pathological Bladder cancer business.industry Proportional hazards model medicine.disease 3. Good health Surgery 030104 developmental biology 030220 oncology & carcinogenesis business Non muscle invasive |
| Zdroj: | Dyrskjøt, L, Reinert, T, Algaba, F, Christensen, E, Nieboer, D, Hermann, G G, Mogensen, K, Beukers, W, Marquez, M, Segersten, U, Høyer, S, Ulhøi, B P, Hartmann, A, Stöhr, R, Wach, S, Nawroth, R, Schwamborn, K, Tulic, C, Simic, T, Junker, K, Harving, N, Petersen, A C, Jensen, J B, Keck, B, Grimm, M-O, Horstmann, M, Maurer, T, Steyerberg, E W, Zwarthoff, E C, Real, F X, Malats, N, Malmström, P-U & Ørntoft, T F 2017, ' Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer : A Prospective Multicentre Validation Study ', European Urology, vol. 72, no. 3, pp. 461-469 . https://doi.org/10.1016/j.eururo.2017.05.040 European Urology, 72(3), 461-469. Elsevier |
| ISSN: | 0302-2838 |
| Popis: | BACKGROUND: Progression of non-muscle-invasive bladder cancer (NMIBC) to muscle-invasive bladder cancer (MIBC) is life-threatening and cannot be accurately predicted using clinical and pathological risk factors. Biomarkers for stratifying patients to treatment and surveillance are greatly needed.OBJECTIVE: To validate a previously developed 12-gene progression score to predict progression to MIBC in a large, multicentre, prospective study.DESIGN, SETTING, AND PARTICIPANTS: We enrolled 1224 patients in ten European centres between 2008 and 2012. A total of 750 patients (851 tumours) fulfilled the inclusion and sample quality criteria for testing. Patients were followed for an average of 28 mo (range 0-76). A 12-gene real-time qualitative polymerase chain reaction assay was performed for all tumours and progression scores were calculated using a predefined formula and cut-off values.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We measured progression to MIBC using Cox regression analysis and log-rank tests for comparing survival distributions.RESULTS AND LIMITATIONS: The progression score was significantly (pCONCLUSIONS: The 12-gene progression score had independent prognostic power beyond clinical and histopathological risk factors, and may help in stratifying NMIBC patients to optimise treatment and follow-up regimens.PATIENT SUMMARY: Clinical use of a 12-gene molecular test for disease aggressiveness may help in stratifying patients with non-muscle-invasive bladder cancer to optimal treatment regimens. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect